249 related articles for article (PubMed ID: 9209441)
1. Donor chimaerism is a strong indicator of disease free survival following bone marrow transplantation for chronic myeloid leukaemia.
Gardiner N; Lawler M; O'Riordan J; De'Arce M; McCann SR
Leukemia; 1997 Apr; 11 Suppl 3():512-5. PubMed ID: 9209441
[TBL] [Abstract][Full Text] [Related]
2. Persistent donor chimaerism is consistent with disease-free survival following BMT for chronic myeloid leukaemia.
Gardiner N; Lawler M; O'Riordan J; DeArce M; Humphries P; McCann SR
Bone Marrow Transplant; 1997 Aug; 20(3):235-41. PubMed ID: 9257892
[TBL] [Abstract][Full Text] [Related]
3. Polymerase chain reaction is highly predictive of relapse in patients following T cell-depleted allogeneic bone marrow transplantation for chronic myeloid leukemia.
Mackinnon S; Barnett L; Heller G
Bone Marrow Transplant; 1996 Apr; 17(4):643-7. PubMed ID: 8722369
[TBL] [Abstract][Full Text] [Related]
4. Detection of minimal residual disease and persistence of host-type hematopoiesis: a study in 28 patients after sex-mismatched, non-T cell-depleted allogeneic bone marrow transplantation for Philadelphia-chromosome positive chronic myelogenous leukemia.
Elmaagacli AH; Becks HW; Beelen DW; Stockova J; Bützler R; Opalka B; Schaefer UW
Bone Marrow Transplant; 1995 Dec; 16(6):823-9. PubMed ID: 8750276
[TBL] [Abstract][Full Text] [Related]
5. Detection of bcr/abl transcripts by RT-PCR and their colorimetric evaluation in chronic myeloid leukemia patients receiving allogeneic bone marrow transplantation.
Santini V; Zoccolante A; Bosi A; Guidi S; Saccardi R; Vannucchi AM; Martinazzo G; Bernabei PA; Ferrini PR
Haematologica; 1996; 81(3):201-7. PubMed ID: 8767524
[TBL] [Abstract][Full Text] [Related]
6. Myeloid mixed chimerism is associated with relapse in bcr-abl positive patients after unmanipulated allogeneic bone marrow transplantation for chronic myelogenous leukemia.
Román J; Serrano J; Jiménez A; Castillejo JA; Reina ML; González MG; Rodríguez MC; García I; Sánchez J; Maldonado J; Torres A
Haematologica; 2000 Feb; 85(2):173-80. PubMed ID: 10681725
[TBL] [Abstract][Full Text] [Related]
7. Distinct patterns of minimal residual disease associated with graft-versus-host disease after allogeneic bone marrow transplantation for chronic myelogenous leukemia.
Pichert G; Roy DC; Gonin R; Alyea EP; Bélanger R; Gyger M; Perreault C; Bonny Y; Lerra I; Murray C
J Clin Oncol; 1995 Jul; 13(7):1704-13. PubMed ID: 7602361
[TBL] [Abstract][Full Text] [Related]
8. Influence of graft-versus-host disease on the eradication of minimal residual leukemia detected by polymerase chain reaction in chronic myeloid leukemia patients after bone marrow transplantation.
Arnold R; Janssen JW; Heinze B; Bunjes D; Hertenstein B; Wiesneth M; Kubanek B; Heimpel H; Bartram CR
Leukemia; 1993 May; 7(5):747-51. PubMed ID: 8483329
[TBL] [Abstract][Full Text] [Related]
9. Autologous reconstitution with BCR-ABL-negative haematopoiesis after T cell-depleted allogeneic BMT for CML.
Serrano J; Román J; Castillejo JA; Sánchez J; Navarro JA; Martín C; Herrera C; Torres A
Bone Marrow Transplant; 1998 Sep; 22(6):599-601. PubMed ID: 9758352
[TBL] [Abstract][Full Text] [Related]
10. Monitoring of lineage-specific chimaerism allows early prediction of response following donor lymphocyte infusions for relapsed chronic myeloid leukaemia.
Gardiner N; Lawler M; O'Riordan JM; Duggan C; De Arce M; McCann SR
Bone Marrow Transplant; 1998 Apr; 21(7):711-9. PubMed ID: 9578312
[TBL] [Abstract][Full Text] [Related]
11. Increasing mixed haematopoietic chimaerism after BMT with total depletion of CD4+ and partial depletion of CD8+ lymphocytes is associated with a higher incidence of relapse.
Serrano J; Román J; Herrera C; Castillejo JA; Navarro JA; Reina ML; González MG; Rodriguez MC; Pascual A; Sánchez J; Torres A
Bone Marrow Transplant; 1999 Mar; 23(5):475-82. PubMed ID: 10100562
[TBL] [Abstract][Full Text] [Related]
12. Molecular basis for therapeutic decisions in chronic myeloid leukemia patients after allogeneic bone marrow transplantation.
Román J; Alvarez MA; Torres A
Haematologica; 2000 Oct; 85(10):1072-82. PubMed ID: 11025600
[TBL] [Abstract][Full Text] [Related]
13. Molecular analysis of transient cytogenetic relapse after allogeneic bone marrow transplantation for chronic myeloid leukaemia.
Lin F; Kirkland MA; van Rhee FV; Chase A; Coulthard S; Bungey J; Goldman JM; Cross NC
Bone Marrow Transplant; 1996 Dec; 18(6):1147-52. PubMed ID: 8971386
[TBL] [Abstract][Full Text] [Related]
14. Frequent detection of BCR-ABL specific mRNA in patients with chronic myeloid leukemia (CML) following allogeneic and syngeneic bone marrow transplantation (BMT).
Gaiger A; Lion T; Kalhs P; Mitterbauer G; Henn T; Haas O; Födinger M; Kier P; Forstinger C; Quehenberger P
Leukemia; 1993 Nov; 7(11):1766-72. PubMed ID: 8231244
[TBL] [Abstract][Full Text] [Related]
15. Allogeneic blood stem cell transplantation in chronic myeloid leukaemia-chronic phase following conditioning with busulphan and cyclophosphamide: a follow up report.
Saikia TK; Parikh PM; Tawde S; Amare-Kadam PS; Rajadhyaksha S; Chhaya S
Natl Med J India; 2004; 17(2):71-3. PubMed ID: 15141598
[TBL] [Abstract][Full Text] [Related]
16. A comparison of chimerism and minimal residual disease between four different allogeneic transplantation methods in patients with chronic myelogenous leukemia in first chronic phase.
Elmaagacli AH; Runkel K; Steckel N; Opalka B; Trenschel R; Seeber S; Schaefer UW; Beelen DW
Bone Marrow Transplant; 2001 Apr; 27(8):809-15. PubMed ID: 11477437
[TBL] [Abstract][Full Text] [Related]
17. Comparative Study of FISH, PCR and Cytogenetics on 25 Patients Submitted to Bone Marrow Transplantation (BMT) for Chronic Myelogenous Leukemia (CML); Which Tests can we Use in Routine Analysis Post BMT?
Palka G; Lawler M; Morizio E; Gardiner N; Stuppia L; De Arce MA; Di Bartolomeo PD; Capodiferro F; Sabatino G; Gatta V; Calabrese G; Cann SR
Hematology; 1998; 3(3):193-203. PubMed ID: 27416528
[TBL] [Abstract][Full Text] [Related]
18. Extended follow-up of patients treated with imatinib mesylate (gleevec) for chronic myelogenous leukemia relapse after allogeneic transplantation: durable cytogenetic remission and conversion to complete donor chimerism without graft-versus-host disease.
DeAngelo DJ; Hochberg EP; Alyea EP; Longtine J; Lee S; Galinsky I; Parekkedon B; Ritz J; Antin JH; Stone RM; Soiffer RJ
Clin Cancer Res; 2004 Aug; 10(15):5065-71. PubMed ID: 15297408
[TBL] [Abstract][Full Text] [Related]
19. Minimal residual disease after bone marrow transplantation for chronic myelogenous leukemia and implications for graft-versus-leukemia effect: a review of recent results.
Miyamura K; Barrett AJ; Kodera Y; Saito H
Bone Marrow Transplant; 1994 Aug; 14(2):201-9. PubMed ID: 7994233
[TBL] [Abstract][Full Text] [Related]
20. Qualitative assessment of mixed chimerism after allogeneic bone marrow transplantation with regard to leukemic relapse.
Kögler G; Hernandez A; Heyll A; Wolf HH; Wernet P
Cancer Detect Prev; 1996; 20(6):601-9. PubMed ID: 8939346
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
